StockData

Relay Therapeutics vs Taysha Gene Therapies

RLAY and TSHA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RLAY and TSHA compare

Relay Therapeutics is the larger company, worth 2.8 times as much as Taysha Gene Therapies ($3.6B against $1.3B).

Relay Therapeutics grew revenue faster over the last twelve months (23.9% versus −32.3% for Taysha Gene Therapies).

Taysha Gene Therapies keeps more of each dollar of sales as profit, with a net margin of −2728% compared with −2764% at Relay Therapeutics.

Relay Therapeutics scores higher on the StockData Score (10 against 5 for Taysha Gene Therapies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRLAYTSHA
Size and price
Market cap$3.6B$1.3B
Share price$16.47$4.00
Change, 1 year162%−3.1%
Change, 5 years−44.8%−68.5%
Beta (5Y)1.962.80
Employees19299
StockData Score
Total score10 (better)5
Valuation score00
Growth score2 (better)1
Performance score2 (better)1
Health score6 (better)3
Dividend score00
Valuation
P/S349×238× (better)
P/B4.1×3.4× (better)
FCF yield–−10.2%
Growth
Revenue growth (TTM)23.9% (better)−32.3%
Revenue growth, 5Y average−28.6%–
Profitability
Operating margin−2999%−2792% (better)
Net margin−2764%−2728% (better)
FCF margin–−2417%
Return on equity−36.8% (better)−47.1%
Return on invested capital−37.1%–
Financial health
Debt / equity0.000.13 (better)
Interest coverage–−3646.6×
Current ratio18.27 (better)17.76
Altman Z-score24.86 (better)7.07
Piotroski F-score45 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions113%91.9%
Held by insiders24.5%10.7%
Insider net buying, 12 months−$129M−$6.1M (better)
Superinvestors holding1–
Short interest, % of float26.4%18.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.